44. Ibogaine with Professor Deborah Mash

This week on the Drug Science podcast, Professor Deborah Mash tells us about Ibogaine. A hallucinogenic compound derived from the roots of a West African shrub, sometimes used as a treatment for heroin or cocaine addiction.

Professor Mash found herself trying to reverse the damage that cocaine had caused on the streets of Miami, Florida. To explore new and novel therapies, she took a flight to Amsterdam to examine whether a West African shrub could be cure to cocaine and heroin dependency.  Since that fateful trip, she’s been at the forefront of Ibogaine and Noribogaine research in the US. Now, she’s bringing that research to the UK for a landmark Ibogaine study in Manchester, England. Could Ibogaine be one of the most clinically significant advances in addiction medicine of the 21st century? 

Deborah Mash is one of the world's foremost experts on the hallucinogenic drug ibogaine. She is the CEO and Founder of DemeRx Inc., a clinical-stage drug development company advancing ibogaine and its active metabolite noribogaine for the treatment of opioid use disorder. DemeRx has partnered with ATAI Life Sciences -- a global biotech platform with a special focus on psychedelic medicine -- to develop ibogaine for those suffering from opioid use disorder. Building on the extensive human data available around ibogaine, DemeRx and ATAI will submit Clinical Trial Applications for a Phase II study in opioid-dependent patients. This joint venture will also develop screening procedures, dosing guidelines, and best practices for opioid withdrawal management to ensure patient safety.

Enrol to the MAC Ibogaine Clinical trial 

DemeRx

Miami’s drug war 

Brain Endowment Bank

National Institute on Drug Abuse (NIDA)

Cocaethylene

Drug Free America 

Howard Lotsof

Noribogaine

Rick Doblin 

Cerebellar Toxicity 

Buprenorphine 

U.S. Food and Drug Administration (FDA)

Psilocybin

MAC Manchester

Alexander Shulgin  

Allopregnanolone (Brexanolone)